Skip to search formSkip to main contentSkip to account menu

BMS225975

Known as: BMS-225975 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

BenzodiazepinesImidazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
BMS-214662 potently induces apoptosis of Chronic Myeloid Leukemia stem and progenitor cells and synergises with tyrosine kinas
Chronic myeloid leukemia (CML), a hematopoietic stem cell disorder, cannot be eradicated by conventional chemotherapy or the… 
2007
2007
The cytotoxic farnesyltransferase inhibitor , BMS-214662 , potently induces apoptosis of Chronic Myeloid Leukaemia stem and progenitor cells and synergises with tyrosine kinase inhibitors
Chronic myeloid leukemia (CML), a hematopoietic stem cell (HSC) disorder, cannot be eradicated by conventional chemotherapy or… 
Highly Cited
2005
Highly Cited
2005
Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways
Farnesyltransferase inhibitors (FTI) have been developed as anticancer drugs and are currently being evaluated in clinical trials… 
2004
2004
Apoptotic and Cytostatic Farnesyltransferase Inhibitors Have Distinct Pharmacology and Efficacy Profiles in Tumor Models
BMS-214662 and BMS-225975 are tetrahydrobenzodiazepine-based farnesyltransferase inhibitors (FTIs) that have nearly identical… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)